18 August, 2026 | Tuesday | News

-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name URC102)’ demonstrated excellent serum uric acid-lo...

26 August, 2026 | Wednesday | News

New Orbitrap Isora workflow integrates mass spectrometry, Vanquish Duo UHPLC System and Isotope Discoverer Software to bring molecular-level isotope ratio analysis to more researchers worldwide Key highlights:...

31 August, 2026 | Monday | News

Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization D...

31 August, 2026 | Monday | News

Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinical operations excellence with advanced digital twin tec...

30 August, 2026 | Sunday | Analysis

METHOD IN BRIEF Outcome evidence in this article is taken from published trial results and approved label language only. No efficacy or outcome claim is sourced from investor presentations, company pipeline de...

28 August, 2026 | Friday | News

Expanded agreement combines PENTAX Medical's continued investment in flexible reusable endoscopy with MAGENTIQ's clinically validated AI capabilities, expanding access to AI-assisted colonoscopy across USA, EME...

24 August, 2026 | Monday | News

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment i...